<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33213069</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>22</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8680</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21228680</ELocationID><Abstract><AbstractText>Sporadic amyotrophic lateral sclerosis (sALS) is a fatal progressive neurodegenerative disease affecting upper and lower motor neurons. Biomarkers are useful to facilitate the diagnosis and/or prognosis of patients and to reveal possible mechanistic clues about the disease. This study aimed to identify and validate selected putative biomarkers in the cerebrospinal fluid (CSF) of sALS patients at early disease stages compared with age-matched controls and with other neurodegenerative diseases including Alzheimer disease (AD), spinal muscular atrophy type III (SMA), frontotemporal dementia behavioral variant (FTD), and multiple sclerosis (MS). SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for protein quantitation, and ELISA for validation, were used in CSF samples of sALS cases at early stages of the disease. Analysis of mRNA and protein expression was carried out in the anterior horn of the lumbar spinal cord in post-mortem tissue of sALS cases (terminal stage) and controls using RTq-PCR, and Western blotting, and immunohistochemistry, respectively. SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed 51 differentially expressed proteins in the CSF in sALS. Receiver operating characteristic (ROC) curves showed CXCL12 to be the most valuable candidate biomarker. We validated the values of CXCL12 in CSF with ELISA in two different cohorts. Besides sALS, increased CXCL12 levels were found in MS but were not altered in AD, SMA, and FTD. Therefore, increased CXCL12 levels in the CSF can be useful in the diagnoses of MS and sALS in the context of the clinical settings. CXCL12 immunoreactivity was localized in motor neurons in control and sALS, and in a few glial cells in sALS at the terminal stage; CXCR4 was in a subset of oligodendroglial-like cells and axonal ballooning of motor neurons in sALS; and CXCR7 in motor neurons in control and sALS, and reactive astrocytes in the pyramidal tracts in terminal sALS. CXCL12/CXCR4/CXCR7 axis in the spinal cord probably plays a complex role in inflammation, oligodendroglial and astrocyte signaling, and neuronal and axonal preservation in sALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andr&#xe9;s-Benito</LastName><ForeName>Pol</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3000-0338</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurosciences, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>M&#xf2;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xed;nguez</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marco</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colomina</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0106-0956</Identifier><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Bellvitge University Hospital-University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-P&#xe9;rez</LastName><ForeName>&#xd3;scar</ForeName><Initials>&#xd3;</Initials><Identifier Source="ORCID">0000-0003-2454-2114</Identifier><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Department, CHUC-Centro Hospitalar e Universit&#xe1;rio de Coimbra, CNC-Center for Neuroscience and Cell Biology; and Faculty of Medicine, University of Coimbra, 3000-456 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldeiras</LastName><ForeName>In&#xea;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Department, CHUC-Centro Hospitalar e Universit&#xe1;rio de Coimbra, CNC-Center for Neuroscience and Cell Biology; and Faculty of Medicine, University of Coimbra, 3000-456 Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Yel&#xe1;mos</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Multiple Sclerosis Unit, Service of Neurology, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerr</LastName><ForeName>Inga</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6722-2463</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center G&#xf6;ttingen, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorens</LastName><ForeName>Franc</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9756-7497</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurosciences, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Irigoyen</LastName><ForeName>Joaqu&#xed;n</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IDISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroproteomics Unit, Proteomics Platform, Proteored-ISCIII, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad P&#xfa;blica de Navarra (UPNA), 31008 Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santamar&#xed;a</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8046-8102</Identifier><AffiliationInfo><Affiliation>IDISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroproteomics Unit, Proteomics Platform, Proteored-ISCIII, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad P&#xfa;blica de Navarra (UPNA), 31008 Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Isidro</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9888-8754</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurosciences, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropathology, Pathologic Anatomy Service, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FISPI17/000809</GrantID><Agency>Institute Carlos III</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501896">ACKR3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054387">Receptors, CXCR</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054387" MajorTopicYN="N">Receptors, CXCR</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAAS</Keyword><Keyword MajorTopicYN="N">CXCL12</Keyword><Keyword MajorTopicYN="N">CXCR4</Keyword><Keyword MajorTopicYN="N">CXCR7</Keyword><Keyword MajorTopicYN="N">S1006A</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33213069</ArticleId><ArticleId IdType="pmc">PMC7698527</ArticleId><ArticleId IdType="doi">10.3390/ijms21228680</ArticleId><ArticleId IdType="pii">ijms21228680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hortob&#xe1;gyi T., Cairns N.J., Kovacs G.G. Neuropathology of Neurodegenerative Diseases. Cambridge University Press; Cambridge, UK: 2014. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration; pp. 209&#x2013;248.</Citation></Reference><Reference><Citation>Schreiber S., Spotorno N., Schreiber F., Acosta-Cabronero J., Kaufmann J., Machts J., Debska-Vielhaber G., Garz C., Bittner D., Hensiek N., et al. Significance of CSF NfL and tau in ALS. J. Neurol. 2018;265:2633&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">30187162</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S., Vacchiano V., Zenesini C., Polischi B., De Pasqua S., Fileccia E., Mammana A., Di Stasi V., Capellari S., Salvi F., et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 2020;267:1699&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">32100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P., Dom&#xed;nguez R., Colomina M.J., Llorens F., Povedano M., Ferrer I. YKL40 in sporadic amyotrophic lateral sclerosis: Cerebrospinal fluid levels as a prognosis marker of disease progression. Aging. 2018;10:2367&#x2013;2382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188478</ArticleId><ArticleId IdType="pubmed">30215603</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D., Volanti P., Brambilla L., Colletti T., Spataro R., La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 2018;265:510&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P., Carlesi C., Giungato P., Puxeddu I., Borroni B., Boss&#xf9; P., Migliorini P., Siciliano G., Boraschi D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J. Neuroinflamm. 2014;11:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T., Yamasaki R., Tanaka M., Matsushita T., Kikuchi H., Isobe N., Ohyagi Y., Kira J.-I. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J. Neuroimmunol. 2010;222:76&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20381883</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C., Gosset P., Brunaud-Danel V., Lassalle P., Degonne B., Dest&#xe9;e A., Defebvre L., Devos D. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. Amyotroph. Lateral Scler. 2009;10:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">19177252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I., Alcolea D., Montal V., Dols-Icardo O., Mu&#xf1;oz L., De Luna N., Tur&#xf3;n-Sans J., Cort&#xe9;s-Vicente E., S&#xe1;nchez-Saudin&#xf3;s M.B., Subirana A., et al. CSF sAPP&#x3b2;, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91:e1619&#x2013;e1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Th&#xe9;z&#xe9;nas M.-L., Charles P.D., Evetts S., Hu M.T., Talbot K., Fischer R., Kessler B.M., Turner M.R. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann. Neurol. 2018;83:258&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Dedeene L., Goossens J., Claeys K.G., Bosch L.V.D., Tournoy J., Van Damme P., Poesen K. Inflammatory markers in cerebrospinal fluid: Independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry. 2019;90:1338&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens F., Th&#xfc;ne K., Tahir W., Kanata E., Diaz-Lucena D., Xanthopoulos K., Kovatsi E., Pleschka C., Garcia-Esparcia P., Schmitz M., et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol. Neurodegener. 2017;12:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5681777</ArticleId><ArticleId IdType="pubmed">29126445</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro K., Tada H., Heilker R., Shirozu M., Nakano T., Honjo T. Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins. Science. 1993;261:600&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">8342023</ArticleId></ArticleIdList></Reference><Reference><Citation>Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 2009;113:6085&#x2013;6093.</Citation><ArticleIdList><ArticleId IdType="pubmed">19380869</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopal S., Kim J., Ahn S., Craig S., Lam C.M., Gerard N.P., Gerard C., Lefkowitz R.G. Beta-arrestin but not G protein-mediated signaling by the &#x201c;decoy&#x201d; receptor CXCR7. Proc. Natl. Acad. Sci. USA. 2010;107:628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818968</ArticleId><ArticleId IdType="pubmed">20018651</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Zhang M., Li Y., Xu D., Wang Y., Song A., Zhu B., Huang Y., Zheng J.C. CXCR7 Mediates Neural Progenitor Cells Migration to CXCL12 Independent of CXCR4. Stem Cells. 2015;33:2574&#x2013;2585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867224</ArticleId><ArticleId IdType="pubmed">25833331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Xu P., Qiu L., Zhang M., Huang Y., Zheng J.C. CXCR7 Participates in CXCL12-mediated Cell Cycle and Proliferation Regulation in Mouse Neural Progenitor Cells. Curr. Mol. Med. 2016;16:738&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5345320</ArticleId><ArticleId IdType="pubmed">27573194</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R.S., Rubin J.B. Immune and nervous system CXCL12 and CXCR4: Parallel roles in patterning and plasticity. Trends Immunol. 2004;25:306&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15145320</ArticleId></ArticleIdList></Reference><Reference><Citation>Petty J.M., Sueblinvong V., Lenox C.C., Jones C.C., Cosgrove G.P., Cool C.D., Rai P.R., Brown K.K., Weiss D.J., Poynter M.E., et al. Pulmonary Stromal-Derived Factor-1 Expression and Effect on Neutrophil Recruitment during Acute Lung Injury. J. Immunol. 2007;178:8148&#x2013;8157.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548653</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Ransohoff R.M. Multiple roles of chemokine CXCL12 in the central nervous system: A migration from immunology to neurobiology. Prog. Neurobiol. 2008;84:116&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2324067</ArticleId><ArticleId IdType="pubmed">18177992</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumm R.K., Rummel J., Junker V., Culmsee C., Pfeiffer M., Krieglstein J., H&#xf6;llt V., Schulz S. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: Isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J. Neurosci. 2002;22:5865&#x2013;5878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757949</ArticleId><ArticleId IdType="pubmed">12122049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonavia R., Bajetto A., Barbero S., Pirani P., Florio T., Schettini G. Chemokines and their receptors in the CNS: Expression of CXCL12/SDF-1 and CXCR4 and their role in astrocyte proliferation. Toxicol. Lett. 2003;139:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628753</ArticleId></ArticleIdList></Reference><Reference><Citation>Banisadr G., Skrzydelski D., Callewaere C., Desarm&#xe9;nien M., Kitabgi P., Rost&#xe8;ne W. Chemokines and chemokine receptors in the brain: Possible implications in neuromodulation and neuroendocrine regulation; Proceedings of the 34th Annual Meeting of Society for Neurosciences; SanDiego, CA, USA. 23&#x2013;27 October 2004.</Citation></Reference><Reference><Citation>Guyon A., Banisadr G., Rovere C., Cervantes A., Kitabgi P., Melik-Parsadaniantz S., Nahon J.L. Complex effects of stromal cell-derived factor-1alpha on melanin-concentrating hormone neuronexcitability. Eur. J. Neurosci. 2005;21:701&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">15733088</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinisch S., Kirby L.G. SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuropharmacology. 2010;58:501&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813394</ArticleId><ArticleId IdType="pubmed">19755127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardelt A.A., Bhattacharyya B.J., Belmadani A., Ren D., Miller R.J. Stromal derived growth factor-1 (CXCL12) modulates synaptic transmission to immature neurons during post-ischemic cerebral repair. Exp. Neurol. 2013;248:246&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773266</ArticleId><ArticleId IdType="pubmed">23811016</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Chang S., Li W., Tang G., Ma Y., Liu Y., Yuan F., Zhang Z., Yang G.-Y., Wang Y. cxcl12-engineered endothelial progenitor cells enhance neurogenesis and angiogenesis after ischemic brain injury in mice. Stem Cell Res. Ther. 2018;9:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948880</ArticleId><ArticleId IdType="pubmed">29751775</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhang H., Lin S., Chen X., Yao Y., Mao X., Shao B., Zhuge Q., Jin K. SDF-1/CXCR7 chemokine signaling is induced in the peri-infarct regions in patients with ischemic stroke. Aging Dis. 2018;9:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963349</ArticleId><ArticleId IdType="pubmed">29896417</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaerve A., M&#xfc;ller H.W. Chemokines in CNS injury and repair. Cell Tissue Res. 2012;349:229&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">22700007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao W., Yi X., Qin J., Tian M., Jin G. CXCL12/CXCR4 axis improves migration of neuroblasts along corpus callosum by stimulating MMP-2 secretion after traumatic brain injury in rats. Neurochem. Res. 2016;41:1315&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pubmed">26801174</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao W., Yi X., Qin J., Tian M., Jin G. CXCL12 promotes proliferation of radial glia like cells after traumatic brain injury in rats. Cytokine. 2020;125:154771.</Citation><ArticleIdList><ArticleId IdType="pubmed">31400639</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Hale J.S., Rich J.N., Ransohoff R.M., Lathia J.D. Chemokine CXCL12 in neurodegenerative diseases: An SOS signal for stem cell-based repair. Trends Neurosci. 2012;35:619&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3461091</ArticleId><ArticleId IdType="pubmed">22784557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pashenkov M., S&#xf6;derstr&#xf6;m M., Link H. Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation. J. Neuroimmunol. 2003;135:154&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">12576236</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A., Gambini C., Mancardi G.L., Uccelli A., Pistoia V. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA. 2004;101:11064&#x2013;11069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503741</ArticleId><ArticleId IdType="pubmed">15263096</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbholz M., Theil D., Cepok S., Hemmer B., Kivis&#xe4;kk P., Ransohoff R.M., Hofbauer M., Farina C., Derfuss T., Hartle C., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129:200&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">16280350</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi R., Howell O.W., Nicholas R., Cruciani C., Castellaro M., Romualdi C., Rossi S., Pitteri M., Benedetti M.D., Gajofatto A., et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann. Neurol. 2018;83:739&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">29518260</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi R., Marastoni D., Rossi S., Castellaro M., Mazziotti V., Pitteri M., Gajofatto A., Monaco S., Benedetti M.D., Calabrese M. Increase of CSF inflammatory profile in a case of highly active multiple sclerosis. BMC Neurol. 2019;19:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764139</ArticleId><ArticleId IdType="pubmed">31558148</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards K.R., Goyal J., Plavina T., Czerkowicz J., Goelz S., Ranger A., Cadavid D., Browning J.L. Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis. PLoS ONE. 2013;8:e81007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835751</ArticleId><ArticleId IdType="pubmed">24278364</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon T.M., Eugenin E.A., Lopez L., Kumar S.S., Hesselgesser J., Raine C.S., Berman J.W. A role for CXCL12 (SDF-1&#x3b1;) in the pathogenesis of multiple sclerosis: Regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J. Neuroimmunol. 2006;177:27&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782208</ArticleId></ArticleIdList></Reference><Reference><Citation>McCandless E.E., Wang Q., Woerner B.M., Harper J.M., Klein R.S. CXCL12 Limits Inflammation by Localizing Mononuclear Infiltrates to the Perivascular Space during Experimental Autoimmune Encephalomyelitis. J. Immunol. 2006;177:8053&#x2013;8064.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114479</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilkha-Falb R., Kaushansky N., Kawakami N., Ben-Nun A. Post-CNS-inflammation expression of CXCL12 promotes the endogenous myelin/neuronal repair capacity following spontaneous recovery from multiple sclerosis-like disease. J. Neuroinflamm. 2016;13:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706716</ArticleId><ArticleId IdType="pubmed">26747276</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel J.R., McCandless E.E., Dorsey D., Klein R.S. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc. Natl. Acad. Sci. USA. 2010;107:11062&#x2013;11067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890706</ArticleId><ArticleId IdType="pubmed">20534485</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbajal K.S., Schaumburg C., Strieter R., Kane J., Lane T.E. Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis. Proc. Natl. Acad. Sci. USA. 2010;107:11068&#x2013;11073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890772</ArticleId><ArticleId IdType="pubmed">20534452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeis T., Howell O., Reynolds R., Schaeren-Wiemers N. Molecular pathology of Multiple Sclerosis lesions reveals a heterogeneous expression pattern of genes involved in oligodendrogliogenesis. Exp. Neurol. 2018;305:76&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">29596844</ArticleId></ArticleIdList></Reference><Reference><Citation>Boroujeni F.B., Pasbakhsh P., Mortezaee K., Pirhajati V., Alizadeh R., Aryanpour R., Madadi S., Kashani I.R. Intranasal delivery of SDF-1&#x3b1;-preconditioned bone marrow mesenchymal cells improves remyelination in the cuprizone-induced mouse model of multiple sclerosis. Cell Biol. Int. 2019;44:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">31631484</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho K.-I., Yoon D., Qiu S., Danziger Z., Grill W.M., Wetsel W.C., Ferreira P.A. Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes. Dis. Model. Mech. 2017;10:559&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451164</ArticleId><ArticleId IdType="pubmed">28100513</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Xue H., Pardo A.C., Mattson M.P., Rao M.S., Maragakis N.J. Impaired SDF1/CXCR4 signaling in glial progenitors derived from SOD1(G93A) mice. J. Neurosci. Res. 2007;85:2422&#x2013;2432.</Citation><ArticleIdList><ArticleId IdType="pubmed">17567884</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovich-Nikitin I., Ezra A., Barbiro B., Rabinovich-Toidman P., Solomon B. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS. J. Neuroinflamm. 2016;13:123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882847</ArticleId><ArticleId IdType="pubmed">27230771</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carvalho M., Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph. Lateral Scler. 2009;10:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">18985466</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lach&#xe9;n-Montes M., Gonz&#xe1;lez-Morales A., Zelaya M.V., P&#xe9;rez-Valderrama E., Aus&#xed;n K., Ferrer I., Fern&#xe1;ndez-Irigoyen J., Santamar&#xed;a E. Olfactory bulb neuroproteomics reveals a chronological perturbation of survival routes and a disruption of prohibitin complex during Alzheimer&#x2019;s disease progression. Sci. Rep. 2017;7:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567385</ArticleId><ArticleId IdType="pubmed">28831118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lach&#xe9;n-Montes M., Gonz&#xe1;lez-Morales A., Iloro I., Elortza F., Ferrer I., Gveric D., Fern&#xe1;ndez-Irigoyen J., Santamar&#xed;a E. Unveiling the olfactory proteostatic disarrangement in Parkinson&#x2019;s disease by proteome-wide profiling. Neurobiol. Aging. 2019;73:123&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">30342273</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillet L.C., Navarro P., Tate S., R&#xf6;st H., Selevsek N., Reiter L., Bonner R., Aebersold R. Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis. Mol. Cell. Proteom. 2012;11 doi: 10.1074/mcp.o111.016717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.o111.016717</ArticleId><ArticleId IdType="pmc">PMC3433915</ArticleId><ArticleId IdType="pubmed">22261725</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyanova S., Temu T., Sinitcyn P., Carlson A., Hein M.Y., Geiger T., Mann M., Cox J. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods. 2016;13:731&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">27348712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I. Brain Banking. In: Aminoff M.J., Daroff R.B., editors. Encyclopedia of the Neurological Sciences. 2nd ed. Academic Press; Oxford, UK: 2014. pp. 467&#x2013;473.</Citation></Reference><Reference><Citation>Strong M.J., Hortob&#xe1;gyi T., Okamoto K., Kato S. Amyotrophic lateral sclerosis, primary lateral sclerosis, and spinal muscular atrophy. In: Dickson D.W., Weller R.O., editors. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. 2nd ed. Wiley-Blackwell; Oxford, UK: 2011. pp. 418&#x2013;433.</Citation></Reference><Reference><Citation>Durrenberger P.F., Fernando F.S., Magliozzi R., Kashefi S.N., Bonnert T.P., Ferrer I., Seilhean D., Nait-Oumesmar B., Schmitt A., Gebicke-Haerter P.J., et al. Selection of novel reference genes for use in the human central nervous system: A BrainNet Europe Study. Acta Neuropathol. 2012;124:893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">22864814</ArticleId></ArticleIdList></Reference><Reference><Citation>Youden W.J. Index for rating diagnostic tests. Cancer. 1950;3:32&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Delong E.R., Delong D.M., Clarke-Pearson D.L. Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics. 1988;44:837.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>